BriaCell to Showcase Positive Clinical Data at 2026 AACR Conference

BriaCell will present four posters at the 2026 AACR Annual Meeting, including one featuring data from its ongoing Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, and two posters highlighting further analyses of Phase 2 data. The company will also present preclinical data related to Bria-OTS+, its next-generation personalized off-the-shelf immunotherapy for cancer. The presentations aim to expand the body of evidence supporting the efficacy and favorable safety profile of BriaCell's novel immunotherapy.